Transforming growth factor beta secretion from primary breast cancer fibroblasts

C. E.P. van Roozendaal, J. G.M. Klijn, B. van Ooijen, C. Claassen, A. M.M. Eggermont, S. C. Henzen-Logmans, J. A. Foekens

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)

Abstract

Transforming growth factor beta (TGF-β) is a hormonally regulated growth inhibitor with autocrine and/or paracrine functions in human breast cancer. In vivo, enhanced immunohistochemical staining of extracellular TGF-β1 has been detected around stromal fibroblasts in response to the antiestrogen treatment. We have investigated the effects of tamoxifen on the production of TGF-β by primary human breast fibroblast cultures in serum-free medium. Highly variable levels of mainly latent TGF-β1 were detected in conditioned media from both tumor and normal tissue derived fibroblasts. Hydroxy-tamoxifen was shown to increase latent TGF-β1 secretion in three of the eight tumor tissue-derived fibroblast cultures. Such effect of hydroxy-tamoxifen was not observed in fibroblast cultures established from normal adjacent breast tissue.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalMolecular and Cellular Endocrinology
Volume111
Issue number1
DOIs
Publication statusPublished - 28 Apr 1995
Externally publishedYes

Keywords

  • Fibroblast
  • Human breast cells
  • Tamoxifen
  • Transforming growth factor-beta

Fingerprint

Dive into the research topics of 'Transforming growth factor beta secretion from primary breast cancer fibroblasts'. Together they form a unique fingerprint.

Cite this